Get the Stockscreener App
7.735
0.96%
-0.075
Pre-market:
7.51
-0.225
-2.91%
Genprex Inc stock is traded at $7.735, with a volume of 11,848.
It is down -0.96% in the last 24 hours and up +1,449% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
See More
Previous Close:
$7.81
Open:
$7.76
24h Volume:
11,848
Relative Volume:
0.03
Market Cap:
$3.91M
Revenue:
-
Net Income/Loss:
$-16.73M
P/E Ratio:
-0.023
EPS:
-335.7162
Net Cash Flow:
$-14.29M
1W Performance:
+7.28%
1M Performance:
+1,449%
6M Performance:
+227.75%
1Y Performance:
-43.21%
1-Day Range:
$7.55
$8.10
1-Week Range:
$6.99
$8.50
52-Week Range:
$0.4229
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
7.735 | 3.94M | 0 | -16.73M | -14.29M | -335.72 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex Inc (GNPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genprex Inc (GNPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genprex Inc (GNPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GNPX|Genprex Inc|Price:7.810|Chg%:+0.440 - TradingKey
TradingKey - TradingKey
GNPX|Genprex Inc|Price:7.735|Chg%:-0.075 - TradingKey
Genprex Inc Revenue Breakdown – LSE:0A8I - TradingView
AMD Stock Price Today, Analysis, News and Trading Ideas - Stocktwits
Gross margin % of Genprex Inc – MUN:2DE1 - TradingView
CapEx per share of Genprex Inc – MUN:2DE1 - TradingView
Dilution adjustment of Genprex Inc – MUN:2DE1 - TradingView
Total debt of Genprex Inc – MUN:2DE1 - TradingView
Total revenue of Genprex Inc – MUN:2DE1 - TradingView
Genprex (GNPX) Virtual Road Show with CEO Rodney Varner Transcript - GuruFocus
Genprex Inc C-Suite Interview with Noble Capital Markets Transcript - GuruFocus
Genprex (GNPX) Channelchek C-Suite Series, CEO Rodney Varner interview with Noble's Dr. Ahu Demir Transcript - GuruFocus
Genprex Inc Global One Media Interview Transcript - GuruFocus
Genprex Inc at H C Wainwright Global Investment Conference (Virtual) Transcript - GuruFocus
Cash flow from financing activities of Genprex Inc – FWB:2DE1 - TradingView
Net income of Genprex Inc – MUN:2DE1 - TradingView
Genprex Inc (FRA:2DE1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Genprex Inc (FRA:2DE1) Stock Earnings Transcripts - GuruFocus
Net income of Genprex Inc – FWB:2DE1 - TradingView
Genprex Inc (STU:2DE1) Stock Price & 30 Year Financial Data - GuruFocus
Genprex Inc (STU:2DE1) Stock Earnings Transcripts - GuruFocus
Genprex Inc (STU:2DE1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Genprex (GNPX) Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss of -$0.64 Per ShareEarnings Call Q&A - dars.gov.et
Genprex Announces Reverse Stock Split Amid Nasdaq Compliance Push - TipRanks
Genprex Inc. (GNPX) Edges Higher Amid Tight Trading RangeAggressive Growth Picks - dars.gov.et
Stock Splits Calendar for: - Yahoo! Finance Canada
Genprex Inc. (GNPX) Slides 5% as Biotech Stock Tests Key SupportFibonacci Arc - dars.gov.et
Genprex Shows Resilience: GNPX Climbs 7.8% on Renewed Biotech InterestAnchored VWAP - DonanımHaber
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Reports Net Loss as Pipeline Development ContinuesROIC Trend Report - DonanımHaber
Genprex Inc. (GNPX) Surges Over 5% as Key Support Holds FirmETF Liquidity - dars.gov.et
Genprex (GNPX) Hovers Near Support After Modest Gain, Consolidation Pattern EmergesGamma Squeeze - dars.gov.et
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Reports Net Loss Per Share of $0.64 Amid Ongoing DevelopmentMargin Guidance - dars.gov.et
GNPX Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss Per Share of $0.64 as Stock Rises 2.06%Quarterly Financial Update - dars.gov.et
GNPX Q1 2026 Earnings: Net Loss of $0.64 Per Share as Stock Climbs 5.03%Forward Guidance Trends - dars.gov.et
Genprex Inc. (GNPX) Stages Modest Recovery, Testing Key Resistance LevelLeveraged ETF Flow - dars.gov.et
Genprex | 8-K: Current report - Moomoo
$Genprex (GNPX.US)$ - Moomoo
GNPX Should I Buy - Intellectia AI
Enterprise value to EBIT forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to sales forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to earnings forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Price to book forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Enterprise value to revenue forward of Genprex, Inc. – NASDAQ:GNPX - TradingView
Genprex Inc Actuals & Estimates (NASDAQ:GNPX) - TradingView
GNPX Q1 2026 Earnings: Pre-Revenue Biotech Reports Net Loss of $0.64 per ShareGuidance Upgrade Report - dars.gov.et
Genprex’s Reqorsa combo secures Canadian patent for lung cancer - Yahoo Finance
GNPX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):